Source
4 developments in the corpus
Latest
Everything in the corpus, newest first.
AUG 13, 2026 · JOURNAL ARTICLE
JAMA
Phase 3 randomized controlled trial with adequate sample size and median 3.2-year follow-up showing SBRT improved bowel quality of life and reduced high-grade genitourinary toxicity, but had lower disease-free survival than MH-IMRT.
Retrospective registry analysis describing focal therapy adoption patterns and characterizing use across risk groups, but providing no efficacy or safety outcomes to support clinical decision-making.
AUG 10, 2026 · JOURNAL ARTICLE
JAMA
Phase 3 RCT with adequately powered, pre-specified primary endpoint showing clinically significant and statistically robust PFS benefit (HR 0.44, p<.001) in a well-defined population, though OS remains immature and generalizability is limited to China.
A rigorous meta-analysis of 1725 patients demonstrates that ctDNA levels are strongly associated with disease-free and overall survival across multiple cancer settings, with consistent hazard ratios and statistical significance, though optimal clinical application remains incompletely defined.